Literature DB >> 33547936

Coronary Artery Dilation in an Asymptomatic Pediatric Patient with COVID19 Antibodies.

Nicole Gerber1,2, Patrick A Flynn3,2, Ralf J Holzer4,5.   

Abstract

We describe a 16-year-old asymptomatic male who presented with coronary artery dilation (z score + 2.3) identified on echo performed solely for presence of COVID-19 antibodies. This case raises the question of whether cardiac screening should be considered for all patients with a history of COVID-19.

Entities:  

Keywords:  COVID-19; Coronary aneurysm

Mesh:

Year:  2021        PMID: 33547936      PMCID: PMC7865102          DOI: 10.1007/s00246-021-02566-5

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


Case Report

A 16-year-old male was referred to our pediatric cardiology clinic after testing positive for COVID-19 IgG antibodies. He had a history of a febrile illness, five months earlier during the initial peak of the COVID-19 pandemic. His symptoms had consisted of a mild cough and diarrhea. He did not require hospitalization, and therefore, never underwent COVID-19 PCR testing at that time. He recovered from the febrile illness in less than a week and remained well thereafter. Two months later during a routine check-up, his pediatrician recommended testing for COVID-19 antibodies, which returned positive. The patient was then referred to pediatric cardiology for screening. An electrocardiogram (EKG) was normal. Echocardiography documented a structurally normal heart, with normal systolic and diastolic function, including normal tissue Doppler and myocardial strain measurement. The left coronary artery measurements were normal, with the left main coronary artery measuring 0.31 cm (Boston z score − 0.78). [1] However, the right coronary artery had a proximal dilation, measuring 0.41 cm (Boston z score + 2.3) [Fig 1].
Fig. 1

Enlarged right coronary artery. Short axis view of the proximal right coronary artery measuring 4.1 mm in diameter, with some distal tapering.

Enlarged right coronary artery. Short axis view of the proximal right coronary artery measuring 4.1 mm in diameter, with some distal tapering. The patient was physically active, playing basketball several times a week without limitations. At this cardiology visit, he was placed on low-dose Aspirin and initially restricted from exercise until a stress test could be performed. Stress test documented a VO2 max of 55.3 (111% predicted). Spirometry, EKG, blood pressure, and heart rate response were normal. Given the normal findings of the stress test, the duration of time since the COVID-19 infection, and the patient’s strong desire to resume physical activities, exercise restrictions were lifted. During this cardiology visit, the patient also had a variety of laboratory investigations performed which revealed a normal Troponin I, normal C-reactive protein, normal erythrocyte sedimentation rate, and a normal b-natriuretic peptide. The only abnormality was an elevated creatine kinase of 3,235 U/L (normal range 46.0–171.0 U/L).

Discussion

COVID-19 has been shown to have cardiac effects in both adults [2] and children, [3] including significant cardiac involvement in pediatric patients who develop Multisystem inflammatory syndrome in children (MIS-C). In a recent article published in the New England Journal of Medicine, Feldstein and colleagues identified cardiovascular involvement in 80% of patients presenting with this entity. [4] Coronary artery aneurysms (with a z score ≥ 2.5) were present in 8% of these patients. [4] It is unclear whether the cardiovascular findings are related to the degree of inflammation and immunological response following an infection with COVID-19, and as such, would only be expected in patients that have a clearly documented inflammatory response within the MIS-C spectrum. In the adult population, it has been recommended that patients with mild to severe COVID-19 disease undergo cardiac evaluation prior to returning to strenuous physical activity. [5-7] In the pediatric population, a more narrow approach has been suggested involving testing only in patients with MIS-C or with moderate to severe disease. [8] However, there is still little data to support these recommendations. This patient likely had a mild presentation of COVID-19, although this was not able to be confirmed by COVID PCR at that time. He did not have any history of MIS-C, and was completely asymptomatic at the time when the dilated right coronary artery was identified by echocardiography. Using the coronary artery z score to determine abnormality does have its limitations. The z score for this patient is borderline elevated (+ 2.3), so it is conceivable that future CT angiography may document a large dominant right coronary artery system without aneurysm. It is also possible that this patient could have had an unrecognized past episodes of asymptomatic Kawasaki’s disease, which has been described. [9] However, as coronary artery aneurysms can lead to rupture [10, 11] or myocardial infarction, [11, 12] they are important to identify and monitor. [10]. Identifying coronary artery dilation, albeit borderline, in a patient with COVID-19 antibodies and a history of only mild COVID-19 infection therefore raises a difficult question regarding the management of pediatric patients with COVID-19. This patient was started on low-dose Aspirin with a plan to continue the medication for a year, with continued echocardiographic monitoring. If the z score remains unchanged over the course of the year, the patient will undergo CT angiography for further characterization. This asymptomatic pediatric patient underwent echocardiography solely due to the presence of COVID-19 antibodies, without notable COVID illness nor clinical suspicion for MIS-C. The patient was found to have borderline coronary artery dilation of unknown significance and will be followed closely by cardiology. The finding of borderline coronary artery dilation in this patient raises the question of the need for cardiac screening in pediatric patients who have had COVID-19 identified either by PCR during active infection, or IgG antibodies following the infection.
  10 in total

1.  Return to play after COVID-19: a sport cardiologist's view.

Authors:  Helder Dores; Nuno Cardim
Journal:  Br J Sports Med       Date:  2020-05-07       Impact factor: 13.800

2.  A Game Plan for the Resumption of Sport and Exercise After Coronavirus Disease 2019 (COVID-19) Infection.

Authors:  Dermot Phelan; Jonathan H Kim; Eugene H Chung
Journal:  JAMA Cardiol       Date:  2020-05-13       Impact factor: 14.676

Review 3.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

4.  The Science Underlying COVID-19: Implications for the Cardiovascular System.

Authors:  Peter P Liu; Alice Blet; David Smyth; Hongliang Li
Journal:  Circulation       Date:  2020-04-15       Impact factor: 29.690

5.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients.

Authors:  H Kato; T Sugimura; T Akagi; N Sato; K Hashino; Y Maeno; T Kazue; G Eto; R Yamakawa
Journal:  Circulation       Date:  1996-09-15       Impact factor: 29.690

6.  Asymptomatic Kawasaki Disease in a 3-Month-Old Infant.

Authors:  Helene Pinches; Katherine Dobbins; Sarah Cantrell; Joseph May; Joseph Lopreiato
Journal:  Pediatrics       Date:  2016-07-01       Impact factor: 7.124

7.  Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study.

Authors:  Jan Marc Orenstein; Stanford T Shulman; Linda M Fox; Susan C Baker; Masato Takahashi; Tricia R Bhatti; Pierre A Russo; Gary W Mierau; Jean Pierre de Chadarévian; Elizabeth J Perlman; Cynthia Trevenen; Alexandre T Rotta; Mitra B Kalelkar; Anne H Rowley
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

8.  Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review.

Authors:  Giulia Sanna; Gaia Serrau; Pier Paolo Bassareo; Paola Neroni; Vassilios Fanos; Maria Antonietta Marcialis
Journal:  Eur J Pediatr       Date:  2020-05-30       Impact factor: 3.183

9.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.

Authors:  Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph
Journal:  N Engl J Med       Date:  2020-06-29       Impact factor: 91.245

10.  Resurgence of sport in the wake of COVID-19: cardiac considerations in competitive athletes.

Authors:  Aaron Baggish; Jonathan A Drezner; Jonathan Kim; Matthew Martinez; Jordan M Prutkin
Journal:  Br J Sports Med       Date:  2020-06-19       Impact factor: 13.800

  10 in total
  2 in total

1.  Incidental Finding of Coronary Artery Dilatation in Children With History of COVID-19 Having Minimal or No Symptoms: Raising Red Flag.

Authors:  Adeel Khalid; Najma Patel; Zain Yusuf Ally; Shaista Ehsan
Journal:  Cureus       Date:  2022-04-21

2.  Mild coronary artery dilatation developed in some children with mild COVID-19 but completely regressed within 3 months.

Authors:  Glykeria Rouva; Eleni Vergadi; Eleftheria Hatzidaki; Ioannis Germanakis
Journal:  Acta Paediatr       Date:  2022-07-04       Impact factor: 4.056

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.